Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2019, Article ID 7213854, 11 pages
https://doi.org/10.1155/2019/7213854
Research Article

Influence of Lineage-Negative Stem Cell Therapy on Articulatory Functions in ALS Patients

1Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, Szczecin, Poland
2Department of Neurology, Pomeranian Medical University, Szczecin, Poland
3Department of General Pathology, Pomeranian Medical University, Szczecin, Poland

Correspondence should be addressed to Wioletta Pawlukowska; lp.2o@answ

Received 26 February 2019; Revised 17 April 2019; Accepted 8 May 2019; Published 2 June 2019

Guest Editor: Jun Li

Copyright © 2019 Wioletta Pawlukowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Hausdorff, A. Lertratanakul, M. E. Cudkowicz, A. L. Peterson, D. Kaliton, and A. L. Goldberger, “Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis,” Journal of Applied Physiology, vol. 88, no. 6, pp. 2045–2053, 2000. View at Publisher · View at Google Scholar
  2. J. R. Bach, “Amyotrophic lateral sclerosis: communication status and survival with ventilatory support,” American Journal of Physical Medicine & Rehabilitation, vol. 72, no. 6, pp. 343–349, 1993. View at Google Scholar
  3. K. M. Yorkston, E. Strand, R. Miller, A. Hillel, and K. Smith, “Speech deterioration in amyotrophic lateral sclerosis: implications for the timing of intervention,” Journal of Medical Speech-Language Pathology, vol. 1, pp. 35–46, 1993. View at Google Scholar
  4. B. J. Traynor, M. B. Codd, B. Corr, C. Forde, E. Frost, and O. M. Hardiman, “Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study,” Archives of Neurology, vol. 57, no. 8, pp. 1171–1176, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Mulligan, J. Carpenter, J. Riddel et al., “Intelligibility and the acoustic characteristics of speech in amyotrophic lateral sclerosis (ALS),” Journal of Speech and Hearing Research, vol. 37, no. 3, pp. 496–503, 1994. View at Publisher · View at Google Scholar
  6. C. R. Watts and M. Vanryckeghem, “Laryngeal dysfunction in amyotrophic lateral sclerosis: a review and case report,” Ear, Nose and Throat Disorders, vol. 1, no. 1, p. 1, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. A. D. Hillel and R. Miller, “Bulbar amyotrophic lateral sclerosis: patterns of progression and clinical management,” Head and Neck, vol. 11, no. 1, pp. 51–59, 1989. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Strong, G. M. Grace, J. B. Orange, and H. A. Leeper, “Cognition, language, and speech in amyotrophic lateral sclerosis: a review,” Journal of Clinical and Experimental Neuropsychology, vol. 18, no. 2, pp. 291–303, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. C. R. Roth, L. E. Glaze, G. S. Goding Jr., and W. S. David, “Spasmodic dysphonia symptoms as initial presentation of amyotrophic lateral sclerosis,” Journal of Voice, vol. 10, no. 4, pp. 362–367, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Okuda, N. Kodama, K. Kawabata, H. Tachibana, and M. Sugita, “Corneomandibular reflex in ALS,” Neurology, vol. 52, no. 8, pp. 1699–1701, 1999. View at Publisher · View at Google Scholar
  11. S. E. Langmore and M. E. Lehman, “Physiologic deficits in the orofacial system underlying dysarthria in amyotrophic lateral sclerosis,” Journal of Speech, Language, and Hearing Research, vol. 37, no. 1, pp. 28–37, 1994. View at Publisher · View at Google Scholar
  12. R. J. Carpenter III, T. J. McDonald, and F. M. Howard Jr., “The otolaryngologic presentation of amyotrophic lateral sclerosis,” Otolaryngology–Head and Neck Surgery, vol. 86, no. 3, pp. 479–484, 1978. View at Publisher · View at Google Scholar
  13. B. Tomik, J. Krupinski, L. Glodzik-Sobanska et al., “Acoustic analysis of dysarthria profile in ALS patients,” Journal of the Neurological Sciences, vol. 169, no. 1-2, pp. 35–42, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Murphy, “Communication strategies of people with ALS and their partners,” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 5, no. 2, pp. 121–126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Langton-Hewer, “The management of motor neuron disease,” in Motor Neuron Disease Biology and Management, P. N. Leigh and M. Swash, Eds., pp. 375–406, SpringerVerlag, London, 1995. View at Publisher · View at Google Scholar
  16. M. McHenry, J. Whatman, and A. Pou, “The effect of botulinum toxin A on the vocal symptoms of spastic dysarthria: a case study,” Journal of Voice, vol. 16, no. 1, pp. 124–131, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. P. K. Holden, D. E. Vokes, M. B. Taylor, J. A. Till, and R. L. Crumley, “Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia,” Annals of Otology, Rhinology & Laryngology, vol. 116, no. 12, pp. 891–896, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Watts, C. Nye, and R. Whurr, “Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review,” Clinical Rehabilitation, vol. 20, no. 2, pp. 112–122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Y. Cui, M. S. Liu, and X. F. Tang, “Single fiber electromyography in 78 patients with amyotrophic lateral sclerosis,” Chinese Medical Journal, vol. 117, no. 12, pp. 1830–1833, 2004. View at Google Scholar
  20. H. Mitsumoto, D. A. Chad, and E. K. Pioro, “Speech and communication management,” in Amyotrophic Lateral Sclerosis, H. Mitsumoto, D. A. Chad, and E. K. Pioro, Eds., pp. 405–420, FA Davis Co, New York, NY, USA, 1998. View at Google Scholar
  21. S. J. Esposito, H. Mitsumoto, and M. Shanks, “Use of palatal lift and palatal augmentation prostheses to improve dysarthria in patients with amyotrophic lateral sclerosis: a case series,” The Journal of Prosthetic Dentistry, vol. 83, no. 1, pp. 90–98, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Ono, M. Hamamura, K. Honda, and T. Nokubi, “Collaboration of a dentist and speech-language pathologist in the rehabilitation of a stroke patient with dysarthria: a case study,” Gerodontology, vol. 22, no. 2, pp. 116–119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Suwaki, K. Nanba, E. Ito, I. Kumakura, and S. Minagi, “Nasal speaking valve: a device for managing velopharyngeal incompetence,” Journal of Oral Rehabilitation, vol. 35, no. 1, pp. 73–78, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. S. Nayak, Y. S. Kim, M. Goldman, H. S. Keirstead, and D. A. Kerr, “Cellular therapies in motor neuron diseases,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1762, no. 11-12, pp. 1128–1138, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Machaliński, P. Lażewski-Banaszak, E. Dąbkowska, E. Paczkowska, M. Gołąb-Janowska, and P. Nowacki, “The role of neurotrophic factors in regeneration of the nervous system,” Neurologia i Neurochirurgia Polska, vol. 46, no. 6, pp. 579–590, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Sobuś, B. Baumert, Z. Litwińska et al., “Safety and feasibility of Lin cells administration to ALS patients: a novel view on humoral factors and miRNA profiles,” International Journal of Molecular Sciences, vol. 19, no. 5, article 1312, 2018. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Paczkowska, K. Kaczyńska, E. Pius-Sadowska et al., “Humoral activity of cord blood-derived stem/progenitor cells: implications for stem cell-based adjuvant therapy of neurodegenerative disorders,” PLoS One, vol. 8, no. 12, article e83833, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Silani, C. Calzarossa, L. Cova, and N. Ticozzi, “Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement?” CNS & Neurological Disorders - Drug Targets, vol. 9, no. 3, pp. 314–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Hajivalili, F. Pourgholi, H. Samadi Kafil, F. Jadidi-Niaragh, and M. Yousefi, “Mesenchymal stem cells in the treatment of amyotrophic lateral sclerosis,” Current Stem Cell Research & Therapy, vol. 11, no. 1, pp. 41–50, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. D. H. Hwang, H. J. Lee, I. H. Park et al., “Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice,” Gene Therapy, vol. 16, no. 10, pp. 1234–1244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. M. M. Harper, S. D. Grozdanic, B. Blits et al., “Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes,” Investigative Opthalmology & Visual Science, vol. 52, no. 7, pp. 4506–4515, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Liu and F. Wang, “Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications,” Frontiers in Immunology, vol. 78, article 1005, 2017. View at Publisher · View at Google Scholar · View at Scopus
  33. G. P. Diniz and D. Z. Wang, “Regulation of skeletal muscle by microRNAs,” Comprehensive Physiology, vol. 6, pp. 1279–1294, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Ganesalingam, J. An, C. E. Shaw, G. Shaw, D. Lacomis, and R. Bowser, “Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS,” Journal of Neurochemistry, vol. 117, no. 3, pp. 528–537, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. M. C. O. Rodrigues, D. G. Hernandez-Ontiveros, M. K. Louis et al., “Neurovascular aspects of amyotrophic lateral sclerosis,” International Review of Neurobiology, vol. 102, pp. 91–106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Ehrhart, A. J. Smith, N. Kuzmin-Nichols et al., “Humoral factors in ALS patients during disease progression,” Journal of Neuroinflammation, vol. 12, no. 1, p. 127, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer, “Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease,” Brain Research, vol. 887, no. 1, pp. 80–89, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Lunnon, J. L. Teeling, A. L. Tutt, M. S. Cragg, M. J. Glennie, and V. H. Perry, “Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration,” The Journal of Immunology, vol. 186, no. 12, pp. 7215–7224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Hu, C. Cao, X.-Y. Qin et al., “Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study,” Scientific Reports, vol. 7, no. 1, p. 9094, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. B. R. Brooks, R. G. Miller, M. Swash, and T. L. Munsat, “El escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis,” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 1, no. 5, pp. 293–299, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Mareschi, I. Ferrero, D. Rustichelli et al., “Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow,” Journal of Cellular Biochemistry, vol. 97, no. 4, pp. 744–754, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Behlau, L. . M. Alves dos Santos, and G. Oliveira, “Cross-cultural adaptation and validation of the voice handicap index into Brazilian Portuguese,” Journal of Voice, vol. 25, no. 3, pp. 354–359, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Bonetti and L. Bonetti, “Cross-cultural adaptation and validation of the Voice Handicap Index into Croatian,” Journal of Voice, vol. 27, no. 1, pp. 130.e7–130.e14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. M. E. Helidoni, T. Murry, J. Moschandreas, C. Lionis, A. Printza, and G. A. Velegrakis, “Cross-cultural adaptation and validation of the voice handicap index into Greek,” Journal of Voice, vol. 24, no. 2, pp. 221–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Schindler, F. Ottaviani, F. Mozzanica et al., “Cross-cultural adaptation and validation of the Voice Handicap Index into Italian,” Journal of Voice, vol. 24, no. 6, pp. 708–714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. B. Trinite and J. Sokolovs, “Adaptation and validation of the Voice Handicap Index in Latvian,” Journal of Voice, vol. 28, no. 4, pp. 452–457, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Pruszewicz, A. Obrębowski, B. Wiskirska-Woźnica, and W. W. Wojnowski, “Sprawie kompleksowej oceny głosu – własna modyfikacja testu samooceny niesprawności głosu (Voice Handicap Idex),” Otolaryngologia Polska, vol. 58, pp. 547–549, 2004. View at Google Scholar
  48. P. Enderby and R. Palmer, Frenchay Dysarthria Assessment 2 edition (FDA-2), English, 2008.
  49. E. Oda, Y. Ohashi, K. Tashiro, Y. Mizuno, H. Kowa, and N. Yanagisawa, “Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis,” No To Shinkei, vol. 48, no. 11, pp. 999–1007, 1996. View at Google Scholar
  50. P. Kaufmann, G. Levy, J. L. P. Thompson et al., “The ALSFRSr predicts survival time in an ALS clinic population,” Neurology, vol. 64, no. 1, pp. 38–43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Cymbaluk-Płoska, A. Chudecka-Głaz, E. Pius-Sadowska et al., “Clinical relevance of NGAL/MMP-9 pathway in patients with endometrial cancer,” Disease Markers, vol. 2017, Article ID 6589262, 8 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  52. J. A. Knibb, N. Keren, A. Kulka et al., “A clinical tool for predicting survival in ALS,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 87, no. 12, pp. 1361–1367, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Byrne, C. Walsh, C. Lynch et al., “Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 82, no. 6, pp. 623–627, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. R. Cannon and J. T. Greenamyre, “The role of environmental exposures in neurodegeneration and neurodegenerative diseases,” Toxicological Sciences, vol. 124, no. 2, pp. 225–250, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. L. L. Neto and A. C. Constantini, “Dysarthria and quality of life in patients with amyotrophic lateral sclerosis,” Revista CEFAC, vol. 19, no. 5, pp. 664–673, 2017. View at Publisher · View at Google Scholar
  56. J. Czarzasta, A. Habich, T. Siwek, A. Czapliński, W. Maksymowicz, and J. Wojtkiewicz, “Stem cells for ALS: an overview of possible therapeutic approaches,” International Journal of Developmental Neuroscience, vol. 57, pp. 46–55, 2017. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Kuhle, R. L. P. Lindberg, A. Regeniter et al., “Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis,” European Journal of Neurology, vol. 16, no. 6, pp. 771–774, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Petrou, Y. Gothelf, Z. Argov et al., “Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials,” JAMA Neurology, vol. 73, no. 3, pp. 337–344, 2016. View at Publisher · View at Google Scholar · View at Scopus
  59. R. T. Bartus and E. M. Johnson Jr., “Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: where have we been and what have we learned?” Neurobiology of Disease, vol. 97, Part B, pp. 156–168, 2017. View at Publisher · View at Google Scholar · View at Scopus
  60. B. P. Prins, A. Abbasi, A. Wong et al., “Investigating the causal relationship of C-reactive protein with 32 complex somatic and psychiatric outcomes: a large-scale cross-consortium Mendelian randomization study,” PLOS Medicine, vol. 13, no. 6, article e1001976, 2016. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Keizman, O. Rogowski, S. Berliner et al., “Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis,” Acta Neurologica Scandinavica, vol. 119, no. 6, pp. 383–389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. C. H. Lu, K. Allen, F. Oei et al., “Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis,” Neurology - Neuroimmunology Neuroinflammation, vol. 3, no. 4, article e244, 2016. View at Publisher · View at Google Scholar
  63. G. Nagel, R. S. Peter, A. Rosenbohm et al., “Adipokines, C-reactive protein and amyotrophic lateral sclerosis - results from a population- based ALS registry in Germany,” Scientific Reports, vol. 7, no. 1, article 4374, 2017. View at Publisher · View at Google Scholar · View at Scopus
  64. S. M. Allan and N. J. Rothwell, “Cytokines and acute neurodegeneration,” Nature Reviews Neuroscience, vol. 2, no. 10, pp. 734–744, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. B. Viviani, S. Bartesaghi, E. Corsini, C. L. Galli, and M. Marinovich, “Cytokines role in neurodegenerative events,” Toxicology Letters, vol. 149, no. 1-3, pp. 85–89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Hattori, E. Tanaka, K. Murase et al., “Tumor necrosis factor stimulates the synthesis and secretion of biologically active nerve growth factor in non-neuronal cells,” Journal of Biological Chemistry, vol. 268, no. 4, pp. 2577–2582, 1993. View at Google Scholar
  67. R. N. Saha, X. Liu, and K. Pahan, “Up-regulation of BDNF in astrocytes by TNF-α: a case for the neuroprotective role of cytokine,” Journal of Neuroimmune Pharmacology, vol. 1, no. 3, pp. 212–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Sriram and J. P. O’Callaghan, “Divergent roles for tumor necrosis factor-α in the brain,” Journal of Neuroimmune Pharmacology, vol. 2, no. 2, pp. 140–153, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. M. K. McCoy and M. G. Tansey, “TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease,” Journal of Neuroinflammation, vol. 5, no. 1, p. 45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Brambilla, G. Guidotti, F. Martorana et al., “Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis,” Human Molecular Genetics, vol. 25, no. 14, pp. 3080–3095, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Toussaint, L. J. Boitano, V. Gathot, M. Steens, and P. Soudon, “Limits of effective cough-augmentation techniques in patients with neuromuscular disease,” Respiratory Care, vol. 54, pp. 359–366, 2009. View at Google Scholar
  72. P. Corcia, P. F. Pradat, F. Salachas et al., “Causes of death in a post-mortem series of ALS patients,” Amyotrophic Lateral Sclerosis, vol. 9, no. 1, pp. 59–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. M. C. Kiernan, S. Vucic, B. C. Cheah et al., “Amyotrophic lateral sclerosis,” The Lancet, vol. 377, no. 9769, pp. 942–955, 2011. View at Publisher · View at Google Scholar · View at Scopus